TY - JOUR
T1 - Preference for aggressive end-of-life care among advanced cancer patients in Wuhan, China
T2 - A cross-sectional study
AU - Liao, Jing
AU - Wu, Bei
AU - Mao, Jing
AU - Ni, Ping
N1 - Funding Information:
Acknowledgments: We expressed our gratitude to all participates for their help and Science Foundation of China (project grant number: 71904056) for its funding.
Funding Information:
This research was funded by the National Natural Science Foundation of China, grant number 71904056.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9/2
Y1 - 2020/9/2
N2 - Life-sustaining treatments (LSTs) and end-of-life (EOL) care’s goal for prolonging one’s life are defined as aggressive EOL care among critically ill patients. They have limited effects and add unnecessary financial burden to advanced cancer patients. A questionnaire survey was conducted to collect information on demographics, disease conditions, preference for LSTs, and goal of EOL care among advanced cancer patients of comprehensive grade-A tertiary hospitals in Wuhan, mainland China. Most patients preferred to accept LSTs when they were in a critical condition, including cardiopulmonary resuscitation (89.9%), mechanical ventilation support (85.7%), nasogastric tube feeding (84.1%), blood transfusion (89.8%), general surgery (87.5%), and hemodialysis (85.8%). Most (88%) preferred prolonging life as the goal of EOL care. Logistic regression showed common influencing factors were participants who completed junior high/high school or below and were financially adequate had higher reference for aggressive EOL care. Patients whose physician had accurately disclosed prognosis; however, showed a decrease trend for aggressive EOL care. Most advanced cancer patients preferred to accept aggressive EOL care. Discussions about prognosis disclosure among physicians and patients should be improved. Education about LSTs’ limitations and comfort-oriented care’s benefits should be promoted among the advanced cancer patients in mainland China.
AB - Life-sustaining treatments (LSTs) and end-of-life (EOL) care’s goal for prolonging one’s life are defined as aggressive EOL care among critically ill patients. They have limited effects and add unnecessary financial burden to advanced cancer patients. A questionnaire survey was conducted to collect information on demographics, disease conditions, preference for LSTs, and goal of EOL care among advanced cancer patients of comprehensive grade-A tertiary hospitals in Wuhan, mainland China. Most patients preferred to accept LSTs when they were in a critical condition, including cardiopulmonary resuscitation (89.9%), mechanical ventilation support (85.7%), nasogastric tube feeding (84.1%), blood transfusion (89.8%), general surgery (87.5%), and hemodialysis (85.8%). Most (88%) preferred prolonging life as the goal of EOL care. Logistic regression showed common influencing factors were participants who completed junior high/high school or below and were financially adequate had higher reference for aggressive EOL care. Patients whose physician had accurately disclosed prognosis; however, showed a decrease trend for aggressive EOL care. Most advanced cancer patients preferred to accept aggressive EOL care. Discussions about prognosis disclosure among physicians and patients should be improved. Education about LSTs’ limitations and comfort-oriented care’s benefits should be promoted among the advanced cancer patients in mainland China.
KW - Advanced cancer patients
KW - Aggressive end-of-life care
KW - End-of-life care goal
KW - Life-sustaining treatments
KW - Preference
UR - http://www.scopus.com/inward/record.url?scp=85090687300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090687300&partnerID=8YFLogxK
U2 - 10.3390/ijerph17186592
DO - 10.3390/ijerph17186592
M3 - Article
C2 - 32927824
AN - SCOPUS:85090687300
SN - 1661-7827
VL - 17
SP - 1
EP - 14
JO - International journal of environmental research and public health
JF - International journal of environmental research and public health
IS - 18
M1 - 6592
ER -